Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases. [PDF]
Cancers (Basel), 2022 Simple Summary Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors are successful cancer therapeutics that impair DNA repair machinery, leading to an accumulation of DNA damage and consequently cell death.
Mekhaeil M, Dev KK, Conroy MJ.
europepmc +2 more sources
Transformer-Based Deep-Learning Algorithm for Discriminating Demyelinating Diseases of the Central Nervous System With Neuroimaging. [PDF]
Front Immunol, 2022 Background Differential diagnosis of demyelinating diseases of the central nervous system is a challenging task that is prone to errors and inconsistent reading, requiring expertise and additional examination approaches.
Huang C +7 more
europepmc +2 more sources
Cannabidiol and Other Cannabinoids in Demyelinating Diseases. [PDF]
Int J Mol Sci, 2021 A growing body of preclinical evidence indicates that certain cannabinoids, including cannabidiol (CBD) and synthetic derivatives, may play a role in the myelinating processes and are promising small molecules to be developed as drug candidates for ...
Navarrete C +4 more
europepmc +2 more sources
Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases [PDF]
Cancer Medicine, 2023 Background Distinguishing between central nervous system lymphoma (CNSL) and CNS infectious and/or demyelinating diseases, although clinically important, is sometimes difficult even using imaging strategies and conventional cerebrospinal fluid (CSF ...
Chisako Iriyama +18 more
doaj +2 more sources
Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases [PDF]
Frontiers in Immunology, 2017 Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig) superfamily, is a myelin protein solely expressed at the outermost surface of myelin sheaths and oligodendrocyte membranes.
Patrick Peschl +4 more
openalex +2 more sources
Peripheral Demyelinating Diseases: From Biology to Translational Medicine
Frontiers in Neurology, 2019 Demyelinating diseases represent a spectrum of disorders that impose significant burden on global economy and society. Generally, the prognosis of these diseases is poor and there is no available cure.
Khidhir Kamil +4 more
doaj +2 more sources
Bibliometric analysis of the intestinal microbiota and demyelinating diseases, particularly multiple sclerosis, since 2014 [PDF]
Frontiers in NeuroscienceBackgroundThe gut–brain axis (GBA) represents a complex, bidirectional communication network that connects the central nervous system (CNS) and the gastrointestinal system.
Ling Chen +4 more
doaj +2 more sources
Pregnancy-Related Immune Changes and Demyelinating Diseases of the Central Nervous System
Frontiers in Neurology, 2019 Demyelinating diseases of the central nervous system comprise a heterogeneous group of autoimmune disorders characterized by myelin loss with relative sparing of axons occurring on a background of inflammation.
Ke Qiu +5 more
doaj +2 more sources
Differential diagnosis of demyelinating diseases: what's new? [PDF]
Arquivos de Neuro-Psiquiatria, 2022 Background: Acquired demyelinating disorders lead to overlapping visual, pyramidal, sensory, autonomic, and cerebellar deficits and may lead to severe disability.
Ana Beatriz Ayroza Galvão Ribeiro Gomes +1 more
doaj +2 more sources
Optic neuritis in demyelinating diseases: study of 38 cases. [PDF]
Arq NeuropsiquiatrFerreira JMC +3 more
europepmc +3 more sources